Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4770-4775, October 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hahnfeldt, P.
Right arrow Articles by Hlatky, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hahnfeldt, P.
Right arrow Articles by Hlatky, L.
[Cancer Research 59, 4770-4775, October 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Tumor Development under Angiogenic Signaling

A Dynamical Theory of Tumor Growth, Treatment Response, and Postvascular Dormancy1

Philip Hahnfeldt, Dipak Panigrahy, Judah Folkman and Lynn Hlatky2

Department of Adult Oncology, Dana-Farber Cancer Institute and Joint Center for Radiation Therapy [P. H., L. H.], and Division of Pediatric Surgery, Children’s Hospital [D. P., J. F.], Harvard Medical School, Boston, Massachusetts 02115

The effects of the angiogenic inhibitors endostatin, angiostatin, and TNP-470 on tumor growth dynamics are experimentally and theoretically investigated. On the basis of the data, we pose a quantitative theory for tumor growth under angiogenic stimulator/inhibitor control that is both explanatory and clinically implementable. Our analysis offers a ranking of the relative effectiveness of these inhibitors. Additionally, it reveals the existence of an ultimate limitation to tumor size under angiogenic control, where opposing angiogenic stimuli come into dynamic balance, which can be modulated by antiangiogenic therapy. The competitive influences of angiogenically driven growth and inhibition underlying this framework may have ramifications for tissue size regulation in general.




This article has been cited by other articles:


Home page
 Journal of the American Animal Hospital AssociationHome page
D. Stefanello, S. Romussi, P. Signorelli, M. Caniatti, M. DiGiancamillo, P. Roccabianca, and G. Avallone
Primary Osseous Melanoma in the Tibia of a Dog
J. Am. Anim. Hosp. Assoc., May 1, 2008; 44(3): 139 - 143.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Abdollahi, C. Schwager, J. Kleeff, I. Esposito, S. Domhan, P. Peschke, K. Hauser, P. Hahnfeldt, L. Hlatky, J. Debus, et al.
Transcriptional network governing the angiogenic switch in human pancreatic cancer
PNAS, July 31, 2007; 104(31): 12890 - 12895.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. K. Sakurai, S. Lee, D. A. Arsenault, V. Nose, J. M. Wilson, J. V. Heymach, and M. Puder
Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy
Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L742 - L747.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. D. Roberts, J. S. Isenberg, L. A. Ridnour, and D. A. Wink
Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis
Clin. Cancer Res., February 1, 2007; 13(3): 795 - 798.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. Folkman
Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin
Sci. Signal., September 26, 2006; 2006(354): pe35 - pe35.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Awale, J. Lu, S. K. Kalauni, Y. Kurashima, Y. Tezuka, S. Kadota, and H. Esumi
Identification of Arctigenin as an Antitumor Agent Having the Ability to Eliminate the Tolerance of Cancer Cells to Nutrient Starvation
Cancer Res., February 1, 2006; 66(3): 1751 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. R. Love and J. E. Niederhuber
Models of Breast Cancer Growth and Investigations of Adjuvant Surgical Oophorectomy
Ann. Surg. Oncol., September 1, 2004; 11(9): 818 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
P. A. Puolakkainen, R. A. Brekken, S. Muneer, and E. H. Sage
Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis
Mol. Cancer Res., April 1, 2004; 2(4): 215 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. K. Rofstad, K. Henriksen, K. Galappathi, and B. Mathiesen
Antiangiogenic Treatment with Thrombospondin-1 Enhances Primary Tumor Radiation Response and Prevents Growth of Dormant Pulmonary Micrometastases after Curative Radiation Therapy in Human Melanoma Xenografts
Cancer Res., July 15, 2003; 63(14): 4055 - 4061.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler
The Role of Prolactin in Mammary Carcinoma
Endocr. Rev., February 1, 2003; 24(1): 1 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. D. Miller, C. J. Sweeney, and G. W. Sledge
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
Ann. Onc., January 1, 2003; 14(1): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Esumi, K. Izuishi, K. Kato, K. Hashimoto, Y. Kurashima, A. Kishimoto, T. Ogura, and T. Ozawa
Hypoxia and Nitric Oxide Treatment Confer Tolerance to Glucose Starvation in a 5'-AMP-activated Protein Kinase-dependent Manner
J. Biol. Chem., August 30, 2002; 277(36): 32791 - 32798.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. A. Rupnick, D. Panigrahy, C.-Y. Zhang, S. M. Dallabrida, B. B. Lowell, R. Langer, and M. J. Folkman
From the Cover: Adipose tissue mass can be regulated through the vasculature
PNAS, August 6, 2002; 99(16): 10730 - 10735.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Hlatky, P. Hahnfeldt, and J. Folkman
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893.
[Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
G. TORTORA and F. CIARDIELLO
Protein Kinase A as Target for Novel Integrated Strategies of Cancer Therapy
Ann. N.Y. Acad. Sci., June 1, 2002; 968(1): 139 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Zhou, R. Mazurchuk, and R. M. Straubinger
Antivasculature Effects of Doxorubicin-containing Liposomes in an Intracranial Rat Brain Tumor Model
Cancer Res., May 1, 2002; 62(9): 2561 - 2566.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Streit, A. E. Stephen, T. Hawighorst, K. Matsuda, B. Lange-Asschenfeldt, L. F. Brown, J. P. Vacanti, and M. Detmar
Systemic Inhibition of Tumor Growth and Angiogenesis by Thrombospondin-2 Using Cell-based Antiangiogenic Gene Therapy
Cancer Res., April 1, 2002; 62(7): 2004 - 2012.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. N. Naumov, I. C. MacDonald, P. M. Weinmeister, N. Kerkvliet, K. V. Nadkarni, S. M. Wilson, V. L. Morris, A. C. Groom, and A. F. Chambers
Persistence of Solitary Mammary Carcinoma Cells in a Secondary Site: A Possible Contributor to Dormancy
Cancer Res., April 1, 2002; 62(7): 2162 - 2168.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Tortora, R. Caputo, V. Damiano, G. Fontanini, D. Melisi, B. Maria Veneziani, F. Zunino, A. R. Bianco, and F. Ciardiello
Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity
Clin. Cancer Res., December 1, 2001; 7(12): 4156 - 4163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Tortora, R. Caputo, V. Damiano, R. Bianco, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, and F. Ciardiello
Combined Blockade of Protein Kinase A and Bcl-2 by Antisense Strategy Induces Apoptosis and Inhibits Tumor Growth and Angiogenesis
Clin. Cancer Res., August 1, 2001; 7(8): 2537 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, G. Trinchieri, C. M. Sehgal, M. D. Feldman, and W. M. F. Lee
Doppler Ultrasound Imaging Detects Changes in Tumor Perfusion during Antivascular Therapy Associated with Vascular Anatomic Alterations
Cancer Res., April 1, 2001; 61(7): 2974 - 2982.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
R. A. Bok, S. Halabi, D. T. Fei, C. R. Rodriquez, D. F. Hayes, N. J. Vogelzang, P. Kantoff, M. A. Shuman, and E. J. Small
Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study
Cancer Res., March 1, 2001; 61(6): 2533 - 2536.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
O. Musso, M. Rehn, N. Théret, B. Turlin, P. Bioulac-Sage, D. Lotrian, J.-P. Campion, T. Pihlajaniemi, and B. Clément
Tumor Progression Is Associated with a Significant Decrease in the Expression of the Endostatin Precursor Collagen XVIII in Human Hepatocellular Carcinomas
Cancer Res., January 1, 2001; 61(1): 45 - 49.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
I. Ding, J. Z. Sun, B. Fenton, W. M. Liu, P. Kimsely, P. Okunieff, and W. Min
Intratumoral Administration of Endostatin Plasmid Inhibits Vascular Growth and Perfusion in MCa-4 Murine Mammary Carcinomas
Cancer Res., January 1, 2001; 61(2): 526 - 531.
[Abstract] [Full Text]

Home page
 JCOHome page
M. S. Gordon
Vascular Endothelial Growth Factor as a Target for Antiangiogenic Therapy
J. Clin. Oncol., November 1, 2000; 18(90001): 45s - 46.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ramanujan, G. C. Koenig, T. P. Padera, B. R. Stoll, and R. K. Jain
Local Imbalance of Proangiogenic and Antiangiogenic Factors: A Potential Mechanism of Focal Necrosis and Dormancy in Tumors
Cancer Res., March 1, 2000; 60(5): 1442 - 1448.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.